-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Legend Biotech, Lowers Price Target to $50

Benzinga·12/12/2025 17:15:39
Listen to the news
Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $83 to $50.